Innovative non-surgical treatment for presbyopia

Article

Ophthalmic drops for presbyopes to be introduced

Presbyopia occurs without regard to other eye conditions. The smooth ciliary body muscles pull and push the lens, adjusting its curvature, and thereby adjusting the eye's focal power to bring objects into focus. As individuals age, the lens becomes stiffer, more resilient to flexure , and the muscular activity in the ciliary body become less powerful. Because these changes result in inadequate adjustment of the lens of the eye for various distances, objects that are close will appear blurry. The major cause of presbyopia is loss of elasticity of the lens of the eye. Loss of ciliary muscle power, however, is also believed to contribute to the problem.

Incurable problem

Bifocal contact lenses are similar to bifocal glasses but with limited success. The top portion of the lens serves as the distance lens while the lower serves as the near vision lens. To prevent rotation while in the eye, bifocal contacts use a specially manufactured type of lens. Good candidates for bifocal lenses are those patients who have a good tear film (moist eyes), good binocular vision (ability to focus both eyes together) and visual acuity in each eye, and no disease or abnormalities in the eyelids.

Multifocal contacts tend to either extend the range of acceptable vision from far to near or provide images of distant and near objects simultaneously over the macula. Many of these contact lens designs have been around for more than half a century.

A third alternative is refractive surgery for presbyopia either by a specific laser paradigm or by refractive lens exchange - replacing the natural lens with a bi- or multifocal intraocular lens.

A fourth alternative is now about to be introduced to the wider public. Presbyeyedrops - Método Benozzi is a medical treatment to correct presbyopia by means of ophthalmic drops. It is a pharmacological treatment for presbyopia that avoids the use of eye glasses, contacts or invasive surgery. It consists of an ophthalmic drop patented by Dr Jorge Benozzi which contains a combination of two drugs: a parasympathomimetic and a nonsteroid antiinflammatory agent. Together, they both act on the ciliary muscle responsible for the necessary changes of the lens in accommodation (or focus).

During his research on the drops for presbyopia, Dr Benozzi investigated the causes of this disease, and found that one cause is related to the progressive decrease in the production of the neurotransmitter responsible for the stimulation of the ciliary muscle in the human eye. By means of this drop, the eye is kick-started, provided with that neurotransmitter that the system stopped producing and in the necessary amount; thereby compensating this deficiency and recovering the compromised near vision.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.